HALO — Halozyme Therapeutics, Inc. Dilution Risk Tracker

Halozyme Therapeutics, Inc. (HALO) has a DilutionScore of 10/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for HALO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for HALO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for HALO alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.